In a retrospective cohort study, researchers investigated the risk of cervical cancer and cervical intraepithelial neoplasia in transmasculine and gender-diverse (TMGD) individuals undergoing testosterone treatment. No cases of cervical cancer were observed in the cohort, suggesting that TMGD individuals on testosterone did not exhibit a higher risk for cervical cancer or severe cervical dysplasia when compared to cisgender women. However, the authors noted the need for further studies with longer follow-up periods and comprehensive data on HPV infection and screening practices.